Individualized and fine-tuned treatment

The medical company that has developed an innovative system for individualized dosing of tablets.

About Sensidose


Sensidose AB is a pharmaceutical company that has developed a system for individualized dosing of tablets, a medical treatment using a dosing device pre-programmed for the patient. The system consists of tablets, containing low dose in each individual tablet. The correct dose is obtained by dosing a specific number of tablets. The tablets are dispensed using an electronic dispenser, programmed by the healthcare provider. The dispenser has a built-in alarm, delivers doses at the preset times and registers all doses delivered and also disease symptoms using rating scales that are easy to use. The company’s technology does not affect the course of the disease but treats the symptoms of the disease.


Information regarding Navamedic’s public takeover offer

Navamedic ASA ("Navamedic") announced on 29 March 2023 a public takeover offer to the shareholders of Sensidose Aktiebolag. Sensidose has published the following information relating to the takeover offer:     For further information, please see Navamedic's...

Sensidose granted reimbursement for Flexilev in Finland

As part of Sensidose's ongoing geographical expansion, the company last autumn applied for reimbursement for Flexilev with the Finnish Pharmaceutical Price Board (Lääkkeiden hintalautakunta). The application has now been granted and the approval is in accordance with...

Upcoming events

1) ScandMODIS, 21-22 April 2023


2) SWEMODIS annual meeting on Parkinson’s Disease and other Movement Disorders, November 2023
(Sensidose will participate)

Contact Us

Sensidose AB
Org. Nr. 556550-3074
Gårdsvägen 8 169 70 Solna
Tel : 010 – 70 77 380

Sensidose AB

Vetenskapsvägen 10
191 38 Sollentuna, Sverige